Firms

Apollo Health Ventures

Apollo Health Ventures

Berlin, Germany · Boston, Massachusetts, USA · Luxembourg · Hamburg, Germany

apollo.vc

Apollo Health Ventures is an early-stage investment and venture-creation platform focused on biotechnology, data-driven drug discovery and health technology addressing aging and age-related disorders. Its public strategy combines scientist-led company formation with investment in outside ventures; neuroscience exposure includes Scripta Therapeutics, Therini Bio, Bloom Science and Samsara Therapeutics. Apollo Ventures Holding GmbH is the exact Hamburg website operator and historical SEC exempt-reporting adviser, CRD313129/SEC802-121213; the website separately identifies Apollo Health Ventures Management GmbH as its German alternative-investment-fund manager. These entities belong to the published Apollo Health Ventures platform and are qualified rather than conflated with Apollo Global Management, Apollo Projects or Apollo Neuroscience. Founded2017 according to the co-founder biography, it publishes offices in Berlin, Luxembourg and Boston. A final ERA filing datedApril20,2026 means the historical SEC exempt-reporting status is not asserted as a current registration. Its own FundII final closing announcement reports USD180M in2021; company founder shares, asset values and offering targets are not additional cash closes. Its current directory separates investment/operations staff from four advisory-board members.

Founded
2017
Type
Venture capital

Funds4

  • Apollo Health Ventures Fund II GmbH & Co. KG$180M

    Exact main/master vehicle named own legal disclosure. Manager announced actual finalUSD180M(EUR157.5M)closing December1,2021. SEC US-feeder report independently confirms this amount is totalmaster including allfeeders, not a separatefeeder180M. Reported funding commitments, not AUM or target.

  • Apollo Health Ventures Feeder II GmbH & Co. KG—

    Exact feeder vehicle named own PRIIPS/manager legal disclosure; closed size and fullclosingday not independently verified. Feeder family channels capital to the sameFundII, not anotherUSD180Mclose.

  • Apollo Health Ventures Fund SCSp$10M

    Luxembourg2024speciallimitedpartnership, GPApolloHealthVentureGPSarl, GPmanagerOleMensching corroborates platform identity. SECJanuary24,2025amendment reports actualsoldUSD10,944,360(convertedEUR), zero remaining andoneinvestor; firstsaleSeptember24,2024. Exactfinalclosingday unknown; no assumptionthisisFundIII or totalcurrentplatformAUM. Relationship/overlapwithearliermainfundnotconfirmed, do not aggregateacrossfundfamilies.

  • Apollo Health Ventures US Feeder II GmbH & Co. KG—

    German US-investor feeder linked to ApolloHealthVenturesManagementGmbH and GP II GmbH in2021SECFormD. FirstsaleNovember15,2021; issuerEUR7,020,000 is included in entiremasterEUR157.5M/USD180M. AmountNULL to avoid portraying totalmaster or feeder contribution as an independent additionalfinalclose.

Team

Operations and support

Alexandra Sharon BauseAlexandra Sharon BauseCo-Founder & Venture Partner
Anne Marije van HartenAnne Marije van HartenInvestment Director
Antoine Boulanger Apollo Health VenturesAntoine Boulanger Apollo Health VenturesPartner
Chris ShepardChris ShepardVenture Partner
Florian HauptFlorian HauptPartner
Gerd HummelGerd HummelVenture Partner
Jan AdamsJan AdamsAdvisory
Jeanne BolgerJeanne BolgerAdvisor
Jens EcksteinJens EcksteinAdvisor
Kevin C. GabelKevin C. GabelHead of Operations & Compliance
Marcel BehringerMarcel BehringerGeneral Counsel
Marianne MertensMarianne MertensPartner
Michelle HohmannMichelle HohmannSenior HR Manager & Recruiter
Nils ReggeNils ReggeCo-Founder & General Partner
Ole MenschingOle MenschingCo-Founder & General Partner
Pascale EedePascale EedeAssociate
Rob Scott Apollo Health VenturesRob Scott Apollo Health VenturesAdvisor
Steven LeunertSteven LeunertPartner & CFO

Co-investing

Investments